The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Pharma executives emphasise that without urgent action, Europe may face a decline and an acceleration in the departure of ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

The letter came days after von der Leyen met with pharma CEOs. In the meeting, Sanofi CEO Paul Hudson criticized European governments for underpaying for innovation, according to an industry ...

Swiss and French pharmaceutical companies Novartis and Sanofi argue that the EU should adjust its drug prices to better align with those in the US.